An industry-academic consortium received a U.S. government contract to develop coded synthetic polymer chemicals like DNA for reliably storing massive amounts of data. . . . → Read More: Synthetic DNA Studied for Mass Data Storage
|
|||||
|
|
Medical and robotics labs at two universities in Pittsburgh are developing a portable, autonomous trauma care device to stabilize wounded military service people in the field. . . . → Read More: A.I., Robotics Studied for Military Trauma System  Comments are closed  Finance, New products  biomedical, computer science, contract, DoD, engineering, life sciences, mathematics, medical device, physical sciences, robotics, software, university 
Two companies are developing a new model for a cloud-based platform that makes possible automated collaborative research with artificial intelligence in synthetic biology. . . . → Read More: Platform to Integrate Robotics, Synthetic Biology, A.I. Comments are closed Finance, Joint ventures/collaborations biomedical, biotechnology, contract, DoD, engineering, genomics, life sciences, mathematics, physical sciences, robotics The first of a series of clinical trials testing inactivated Zika particles as a vaccine to protect against the live Zika virus is recruiting participants. . . . → Read More: Zika Vaccine Clinical Trial Underway One comment - (Comments are closed) New products, Regulations biomedical, clinical trials, contract, life sciences, manufacturing, NIH, pharmaceuticals, preclinical Biomedical Advanced Research and Development Authority, or BARDA, signed agreements worth $67 million to develop new treatments and diagnostics for urgent drug-resistant infections. . . . → Read More: Health Agency Funds Drug-Resistant Bacteria R&D Comments are closed Finance biomedical, clinical trials, contract, health care, life sciences, medical device, pharmaceuticals Electron-microscope image of the 2009 H1N1 influenza virus (CDC.gov) 5 October 2015. A clinical trial testing a synthetic antibody designed to treat influenza A shows the treatment is effective in reducing the spread of flu viruses in humans. Visterra Inc., the therapy’s designer, also received a contract valued as much as $204.5 million . . . → Read More: Influenza A Therapy Shown Working in Trial Comments are closed Finance, Regulations biomedical, biotechnology, clinical trials, contract, entrepreneurs, life sciences, pharmaceuticals, university Scanning electron micrograph shows Ebola virus budding on monkey kidney cells (Defense.gov) 21 September 2015. Regeneron Pharmaceuticals Inc. received a contract from the U.S. Department of Health and Human Services to develop an engineered antibody designed to treat Ebola infections. The initial $17 million contract from HHS’s Biomedical Advanced Research and Development Authority . . . → Read More: Regeneron to Develop Antibody Therapy for Ebola One comment - (Comments are closed) Finance, New products Africa, biomedical, biotechnology, contract, FDA, genomics, life sciences, pharmaceuticals, preclinical Ebola health care workers in Guinea (European Commission-ECHO/USIAD) 31 October 2014. A biodefense unit of the U.S. Department of Defense awarded a contract to vaccine maker Profectus BioSciences Inc. for development and testing of a vaccine protecting against the two major Ebola strains and related Marburg viruses. The $9.5 million contract with the . . . → Read More: Ebola-Marburg Vaccine Development, Testing Contract Awarded Comments are closed Finance biomedical, clinical trials, contract, DoD, FDA, licensing, life sciences, NIH, pharmaceuticals, university Scanning electron micrograph image of MRSA bacteria (Janice Haney Carr, Centers for Disease Control and Prevention) Enanta Pharmaceuticals, a biotechnology company in Watertown, Massachusetts, is starting an early-stage clinical trial of an antibiotic to treat methicillin-resistant Staphylococcus aureus or MRSA infections. The drug, code-named EDP-788, is being developed under a contract with National . . . → Read More: Clinical Trial to Test Safety of MRSA Drug Candidate Comments are closed New products, Regulations biomedical, biotechnology, clinical trials, contract, life sciences, NIH, pharmaceuticals Marburg virus (U.S. Centers for Disease Control and Prevention) BioCryst Pharmaceuticals Inc., a developer of drugs for infectious and rare diseases in Durham, North Carolina, says National Institutes of Health (NIH) is continuing its contract with the company to develop a treatment for Marburg virus, the cause of a rare but dangerous tropical . . . → Read More: NIH Funding Further Marburg Virus Therapy Development Comments are closed Finance biomedical, biotechnology, contract, FDA, life sciences, NIH, pharmaceuticals |
||||
|
Copyright © 2020 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||